809 related articles for article (PubMed ID: 29461447)
41. Development of coronary artery lesions in indolent Kawasaki disease following initial spontaneous defervescence: a retrospective cohort study.
Takahashi T; Sakakibara H; Morikawa Y; Miura M
Pediatr Rheumatol Online J; 2015 Nov; 13(1):44. PubMed ID: 26530040
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
[TBL] [Abstract][Full Text] [Related]
43. Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis.
Dionne A; Burns JC; Dahdah N; Tremoulet AH; Gauvreau K; de Ferranti SD; Baker AL; Son MB; Gould P; Fournier A; Newburger JW; Friedman KG
Pediatrics; 2019 Jun; 143(6):. PubMed ID: 31048414
[TBL] [Abstract][Full Text] [Related]
44. Assessment of risk factors for Korean children with Kawasaki disease.
Kim JJ; Hong YM; Yun SW; Han MK; Lee KY; Song MS; Lee HD; Kim DS; Sohn S; Ha KS; Hong SJ; Kim KJ; Park IS; Jang GY; Lee JK;
Pediatr Cardiol; 2012 Apr; 33(4):513-20. PubMed ID: 22105492
[TBL] [Abstract][Full Text] [Related]
45. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V
Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995
[TBL] [Abstract][Full Text] [Related]
46. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
Samadli S; Liu FF; Mammadov G; Wang JJ; Liu HH; Wu YF; Luo HH; Wu Y; Chen WX; Zhang DD; Wei W; Hu P
Pediatr Rheumatol Online J; 2019 Jul; 17(1):53. PubMed ID: 31366406
[TBL] [Abstract][Full Text] [Related]
47. Serum IL-41 might be a biomarker for IVIG resistance and coronary artery lesions in Kawasaki disease.
Duan Y; Li H; Luo D; Jiang J; Liu B; Li G
Int Immunopharmacol; 2023 Sep; 122():110600. PubMed ID: 37423157
[TBL] [Abstract][Full Text] [Related]
48. Plasma exchange and infliximab as a third-line therapy for refractory infantile Kawasaki disease.
Ansai H; Masuda H; Nakao H; Nishimura N; Kubota M
Pediatr Int; 2022 Jan; 64(1):e15226. PubMed ID: 35831245
[TBL] [Abstract][Full Text] [Related]
49. The therapeutic window of intravenous immunoglobulin (IVIG) and its correlation with clinical outcomes in Kawasaki disease: a systematic review and meta-analysis.
Li Z; Cai J; Lu J; Wang M; Yang C; Zeng Z; Tang Q; Li J; Tang W; Luo H; Pan G; Zeng X
Ital J Pediatr; 2023 Apr; 49(1):45. PubMed ID: 37038188
[TBL] [Abstract][Full Text] [Related]
50. Difference in Risk Factors for Subtypes of Acute Cardiac Lesions Resulting from Kawasaki Disease.
Yamashita M; Ae R; Yashiro M; Aoyama Y; Sano T; Makino N; Nakamura Y
Pediatr Cardiol; 2017 Feb; 38(2):375-380. PubMed ID: 27878631
[TBL] [Abstract][Full Text] [Related]
51. Interleukin-18 and coronary artery lesions in patients with Kawasaki disease.
Weng KP; Hsieh KS; Huang SH; Ou SF; Lai TJ; Tang CW; Lin CC; Ho TY; Liou HH; Ger LP
J Chin Med Assoc; 2013 Aug; 76(8):438-45. PubMed ID: 23769880
[TBL] [Abstract][Full Text] [Related]
52. AST-to-ALT ratio and coronary artery lesions among patients with Kawasaki disease.
Cao L; Tang YJ; Gang M; Ma J; Qian WG; Xu QQ; Lv HT
World J Pediatr; 2021 Dec; 17(6):659-668. PubMed ID: 34792780
[TBL] [Abstract][Full Text] [Related]
53. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
54. Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis.
Chen S; Dong Y; Kiuchi MG; Wang J; Li R; Ling Z; Zhou T; Wang Z; Martinek M; Pürerfellner H; Liu S; Krucoff MW
JAMA Pediatr; 2016 Dec; 170(12):1156-1163. PubMed ID: 27749951
[TBL] [Abstract][Full Text] [Related]
55. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.
Burns JC; Song Y; Bujold M; Shimizu C; Kanegaye JT; Tremoulet AH; Franco A
Clin Exp Immunol; 2013 Dec; 174(3):337-44. PubMed ID: 23901839
[TBL] [Abstract][Full Text] [Related]
56. Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in northwest India.
Pilania RK; Jindal AK; Johnson N; Prithvi A; Vignesh P; Suri D; Rawat A; Gupta A; Singh S
Rheumatology (Oxford); 2021 Jul; 60(7):3413-3419. PubMed ID: 33221920
[TBL] [Abstract][Full Text] [Related]
57. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[TBL] [Abstract][Full Text] [Related]
58. [Risk factors for coronary artery lesions in children with Kawasaki disease].
Li Y; Wang XM; Liu YL; Shi K; Yang YF; Guo YH
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec; 14(12):938-41. PubMed ID: 23234782
[TBL] [Abstract][Full Text] [Related]
59. Association between serum miR-221-3p and intravenous immunoglobulin resistance in children with Kawasaki disease.
Jing F; Weng H; Pei Q; Zhang J; Liu R; Yi Q
Clin Exp Med; 2022 Nov; 22(4):621-628. PubMed ID: 35039938
[TBL] [Abstract][Full Text] [Related]
60. Serum amyloid A as a biomarker for immunoglobulin resistance in Kawasaki disease.
Huang XB; Zhao S; Liu ZY; Xu YY; Deng F
Ann Med; 2023; 55(2):2264315. PubMed ID: 37870383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
